California Public Employees Retirement System grew its position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 2.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,800 shares of the specialty pharmaceutical company’s stock after buying an additional 1,800 shares during the quarter. California Public Employees Retirement System owned 0.24% of AMAG Pharmaceuticals worth $1,524,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of AMAG. OppenheimerFunds Inc. raised its position in shares of AMAG Pharmaceuticals by 101.1% in the 1st quarter. OppenheimerFunds Inc. now owns 17,575 shares of the specialty pharmaceutical company’s stock worth $396,000 after acquiring an additional 8,836 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of AMAG Pharmaceuticals by 1.6% in the 1st quarter. Principal Financial Group Inc. now owns 261,929 shares of the specialty pharmaceutical company’s stock worth $5,906,000 after acquiring an additional 4,008 shares in the last quarter. Wellington Management Group LLP raised its position in shares of AMAG Pharmaceuticals by 233.5% in the 1st quarter. Wellington Management Group LLP now owns 161,739 shares of the specialty pharmaceutical company’s stock worth $3,648,000 after acquiring an additional 113,240 shares in the last quarter. Teachers Advisors LLC raised its position in shares of AMAG Pharmaceuticals by 3.6% in the 1st quarter. Teachers Advisors LLC now owns 62,055 shares of the specialty pharmaceutical company’s stock worth $1,399,000 after acquiring an additional 2,164 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of AMAG Pharmaceuticals by 143.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 18,280 shares of the specialty pharmaceutical company’s stock worth $412,000 after acquiring an additional 10,759 shares in the last quarter.

AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at $13.50 on Tuesday. AMAG Pharmaceuticals, Inc. has a 1 year low of $11.93 and a 1 year high of $36.83. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 0.64% and a negative net margin of 35.35%. The company had revenue of $158.39 million for the quarter, compared to analyst estimates of $158.83 million. During the same period in the prior year, the company posted $1.45 EPS. The firm’s quarterly revenue was up 24.3% compared to the same quarter last year. equities research analysts anticipate that AMAG Pharmaceuticals, Inc. will post -1.26 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “California Public Employees Retirement System Raises Holdings in AMAG Pharmaceuticals, Inc. (AMAG)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.watchlistnews.com/california-public-employees-retirement-system-raises-holdings-in-amag-pharmaceuticals-inc-amag/1684667.html.

AMAG has been the subject of several recent research reports. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research report on Wednesday, October 4th. Jefferies Group LLC reissued a “buy” rating and issued a $16.00 price target on shares of AMAG Pharmaceuticals in a research report on Sunday. Deutsche Bank AG reissued a “hold” rating and issued a $24.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, August 31st. BidaskClub lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Finally, Cowen and Company reissued a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Thursday, August 10th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the company. AMAG Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $24.00.

AMAG Pharmaceuticals Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.